Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.40 |
| ▸ | FAP | Q12884 | 5/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16925417 | 0.94 | MAP1LC3B (0.42) | MAP1LC3BSIRT2SIRT1SIRT3FAP | |
| SCHEMBL18893500 | 0.93 | MAP1LC3B (0.40) | MAP1LC3BSIRT2SIRT1SIRT3FAP | |
| SCHEMBL18893501 | 0.93 | MAP1LC3B (0.40) | MAP1LC3BSIRT2SIRT1SIRT3FAP | |
| SCHEMBL16330578 | 0.92 | MAP1LC3B (0.41) | MAP1LC3BSIRT2SIRT1SIRT3FAP | |
| SCHEMBL26009307 | 0.91 | MAP1LC3B (0.40) | MAP1LC3BSIRT2SIRT1SIRT3FAP | |
| SCHEMBL26008568 | 0.91 | MAP1LC3B (0.40) | MAP1LC3BSIRT2SIRT1SIRT3FAP | |
| SCHEMBL9943154 | 0.90 | FURIN (0.46) | MAP1LC3BFAP | |
| SCHEMBL13002105 | 0.90 | FURIN (0.39) | MAP1LC3BFAP | |
| SCHEMBL10270090 | 0.90 | FURIN (0.39) | MAP1LC3BFAP | |
| SCHEMBL30697716 | 0.89 | FURIN (0.40) | MAP1LC3BFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221205-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180079769-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221205-B2 | Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides | GALNT3, B3GAT3, CSGALNACT1 | MAP1LC3B 4284/4885SIRT2 3885/4885SIRT1 3835/4885 |
| US-20180079769-A1 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | GALNT3, CSGALNACT1, FUT6 | MAP1LC3B 4176/4885SIRT2 3653/4885SIRT1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.